ClinicalTrials.gg
RecruitingNCT07142343Updated Apr 13, 2026

A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

A Phase 4 interventional study of Pozelimab in CHAPLE Disease, sponsored by Regeneron Pharmaceuticals. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
1 Year to 5 Years
Sex
All
01

Study summary

This study is researching a drug called pozelimab (called "study drug"). The main aim of this study is to monitor the safety and tolerability of the study drug.

The study is focused on young children 1 to 5 years of age, who have CHAPLE disease. CHAPLE is a very rare hereditary disease that can cause potentially life-threatening symptoms related to the stomach and intestines (gastrointestinal symptoms), and symptoms related to the heart and blood vessels (cardiovascular symptoms).

The study is also looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the study drug blocks Complement 5 (C5) in the body
  • Whether the study drug changes the level of a substance called CH50 measured in the blood
  • Whether the study drug changes the levels of albumin and other proteins
  • Whether the body makes antibodies against study drug, which could make the study drug less effective or could lead to side effects
02

Conditions studied

  • CHAPLE Disease

Keywords

  • CD55-deficient PLE (CHAPLE disease)
  • CD55 loss-of-function mutation
  • Complement hyperactivation
  • Angiopathic thrombosis
  • Protein-losing enteropathy
  • Total Complement Hemolytic Activity Assay (CH50)
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical diagnosis of CD55-deficient CHAPLE disease as described in the protocol
  2. Parent(s)/legal guardian(s) are willing and able to comply with participant's clinic visits and study-related procedures, including participant's completion of the full series of meningococcal vaccinations required per protocol.
  3. Parent(s)/legal guardian(s) are willing to provide written
  4. Participant has active CHAPLE disease as described in the protocol

Key Exclusion Criteria:

  1. History of meningococcal infection
  2. No documented meningococcal quadrivalent (serotype ACWY) vaccination prior to screening and participant's parent(s)/legal guardian(s) are unwilling for participant to undergo vaccination during the study as described in the protocol
  3. No documented vaccination for Haemophilus influenzae and Streptococcus pneumoniae if applicable based on local practice or guidelines prior to screening as described in the protocol
  4. Prior treatment with a complement inhibitor as described in the protocol
  5. Presence of a concomitant disease that leads to hypoproteinemia or secondary intestinal lymphangiectasia as described in the protocol

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Active CHAPLE

    Drug: Pozelimab

Interventions

  • Administered per the protocol

    Also known as: VEOPOZ

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Event (TEAEs)

    Time frame: Through week 52

  2. Severity of TEAEs

    Time frame: Through week 52

Secondary outcomes

  1. Concentrations of total pozelimab

    Time frame: Through week 52

  2. Concentrations of total C5 in serum

    Time frame: Through week 52

  3. Absolute change from baseline of albumin concentration in serum

    Time frame: Through week 52

  4. Percent change from baseline of albumin concentration in serum

    Time frame: Through week 52

  5. Absolute change from baseline of total protein

    Time frame: Through week 52

  6. Percent change from baseline of total protein

    Time frame: Through week 52

  7. Absolute change from baseline of total Immunoglobulin G (IgG)

    Time frame: Through week 52

  8. Percent change from baseline of total IgG

    Time frame: Through week 52

  9. Incidence of Anti-Drug Antibody (ADA) to pozelimab over time

    Time frame: Through week 52

  10. Titer of ADA to pozelimab over time

    Time frame: Through week 52

  11. Change from baseline of total complement activity CH50 over time

    Time frame: Through week 52

  12. Percent change from baseline of CH50 over time

    Time frame: Through week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Feb 2030, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartActual
Mar 19, 2026
Primary completionEst.
Feb 12, 2030
CompletionEst.
Feb 12, 2030
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142343
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Mar 19, 2026
Primary completion
Feb 12, 2030 (estimated)
Completion
Feb 12, 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion